I
Invetx
Bringing the best of biopharma to animal health through closing the innovation gap between animal and human biotechnology
About Invetx
Invetx is a pioneering startup operating in the biotechnology sector, specifically focusing on animal health. The company's primary objective is to develop protein-based therapeutics for veterinary care, which is a novel approach in the industry. Invetx's target market includes both pets and farm animals, with a dual focus on improving veterinary care and promoting sustainable health and productivity in farm animals.
The company operates by partnering with leading biotechnology firms, leveraging their expertise and capabilities to discover and develop advanced veterinary biotherapeutics. This collaborative business model allows Invetx to tap into a wealth of knowledge and resources, thereby accelerating the development of innovative therapies.
Invetx's revenue model is likely based on the commercialization of these therapies. Once a therapy is developed and approved, it can be sold to veterinary clinics, animal health companies, and potentially directly to pet owners or farmers. The company's unique cross-disciplinary team, which includes R&D leaders from both human biotech and animal health sectors, positions it well to deliver on its ambitious goals.
Invetx is based in Boston, MA, and is backed by dedicated investors. This financial support, combined with the company's extensive network of industry experts and close collaboration with veterinary scientists and clinicians, makes it an attractive partner for other companies and experts in the field.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Boston, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 64.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2024 | $520M | $520M | Dechra Pharmaceuticals | ↗ |
| SERIES BOther financing | May 2022 | $61M | $242M | Anterra Capital · Tekla Capital Management · Novo Holdings · F-Prime | ↗ |
Growth signals
Latest recorded traffic for Invetx is 910 monthly website visits, down 52.1% over the last three months. Invetx's team declined 52.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Anterra Capital
WuXi Biologics- TMTekla Capital Management
AbCellera Biologics
Casdin Capital
Novo Holdings
F-Prime
Eight Roads Ventures
Other known investors1 additional known investor
Dechra Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Invetx on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Invetx’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







